STEMPOINT CAPITAL LP — 13F Holdings & Portfolio

CIK 1952142 · latest 13F-HR filed 2026-08-14

STEMPOINT CAPITAL LP manages $580.5M in 13F-reported U.S. long-equity assets across 85 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are TNGX (6.59%), ABVX (6.51%), RVMD (5.16%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 25 new positions and exited 22; 26 existing positions rose in reported value and 21 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$580.5M

Long-equity book

Holdings
85

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+25 / −22 / ↑26 / ↓21

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 41.2%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 30, 2026.

Assets Under Management
$761.3M
Discretionary
$761.3M
Employees
7
Accounts
8
Address
520 MADISON AVENUE
19TH FLOOR
NEW YORK, NY 10022
Phone
(212) 540-4099
Name Title / Status Ownership Type
GORYNSKI, ROBERT, PETER ControlCHIEF FINANCIAL OFFICER
since Aug 2023
Less than 5%Individual
ROAN, KEVIN, PATRICK ControlCHIEF COMPLIANCE OFFICER
since Jan 2025
Less than 5%Individual
ROSS, MICHELLE, AVRA ControlCHIEF INVESTMENT OFFICER AND MANAGING PARTNER
since Sep 2022
75% or moreIndividual
STEMPOINT CAPITAL MANAGEMENT GP LLC ControlGENERAL PARTNER
since Sep 2022
Less than 5%Domestic Entity
TAN, SEAN, CHUA ControlPRESIDENT AND MANAGING PARTNER
since Sep 2022
25–50%Individual
ROSS, MICHELLE, AVRA Control
Indirect owner via STEMPOINT CAPITAL MANAGEMENT GP LLC
MANAGING MEMBER
since Sep 2022
75% or moreIndividual
Ownership & leadership changes · 3 filings with changes since Nov 15, 2022

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Jan 2, 2025 filing
  • AddedROAN, KEVIN, PATRICK · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedTAN, SEAN, CHUA · title CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, AND MANAGING PARTNER → PRESIDENT AND MANAGING PARTNER
Sep 27, 2024 filing
  • ChangedGORYNSKI, ROBERT, PETER · title CFO → CHIEF FINANCIAL OFFICER
  • ChangedROSS, MICHELLE, AVRA · title CIO & MANAGING PARTNER → CHIEF INVESTMENT OFFICER AND MANAGING PARTNER
  • ChangedROSS, MICHELLE, AVRA · indirect via STEMPOINT CAPITAL MANAGEMENT GP LLC: title CIO & MANAGING PARTNER → MANAGING MEMBER
  • ChangedSTEMPOINT CAPITAL MANAGEMENT GP LLC · title GP OF THE IM → GENERAL PARTNER
  • ChangedTAN, SEAN, CHUA · title CCO, COO AND MANAGING PARTNER → CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, AND MANAGING PARTNER
Sep 13, 2023 filing
  • AddedGORYNSKI, ROBERT, PETER · CFO · Less than 5% · control person
Nov 15, 2022 filing (earliest on record)
  • ListedROSS, MICHELLE, AVRA · CIO & MANAGING PARTNER · 75% or more · control person
  • ListedROSS, MICHELLE, AVRA · CIO & MANAGING PARTNER · 75% or more · indirect via STEMPOINT CAPITAL MANAGEMENT GP LLC · control person
  • ListedSTEMPOINT CAPITAL MANAGEMENT GP LLC · GP OF THE IM · Less than 5% · control person
  • ListedTAN, SEAN, CHUA · CCO, COO AND MANAGING PARTNER · 25–50% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

STEMPOINT CAPITAL LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 TANGO THERAPEUTICS INC TNGX 87583X109 $38.2M 6.59% 1,223,019 SH
2 ABIVAX SA ABVX 00370M103 $37.8M 6.51% 283,657 SH
3 REVOLUTION MEDICINES INC RVMD 76155X100 $30.0M 5.16% 159,943 SH
4 ERASCA INC ERAS 29479A108 $28.7M 4.94% 1,565,913 SH
5 TYRA BIOSCIENCES INC TYRA 90240B106 $20.2M 3.48% 632,754 SH
6 DIANTHUS THERAPEUTICS INC DNTH 252828108 $19.6M 3.37% 200,851 SH
7 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $17.6M 3.03% 346,914 SH
8 MINERALYS THERAPEUTICS INC MLYS 603170101 $16.3M 2.80% 602,686 SH
9 BIOHAVEN LTD BHVN G1110E107 $15.8M 2.73% 1,064,200 SH
10 KINIKSA PHARMACEUTICALS INTL KNSA G52694109 $13.4M 2.30% 209,234 SH
11 SCHOLAR ROCK HLDG CORP SRRK 80706P103 $13.2M 2.27% 239,146 SH
12 ALKERMES PLC ALKS G01767105 $13.0M 2.24% 248,015 SH
13 FIRST TRACKS BIOTHERAPEUTICS TRAX 337185102 $12.5M 2.16% 622,723 SH
14 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $12.5M 2.15% 37,243 SH
15 ROIVANT SCIENCES LTD ROIV G76279101 $12.3M 2.12% 348,408 SH
16 BIOAGE LABS INC BIOA 09077V100 $11.4M 1.96% 464,171 SH
17 CG ONCOLOGY INC CGON 156944100 $11.3M 1.95% 159,349 SH
18 ORUKA THERAPEUTICS INC ORKA 687604108 $11.1M 1.91% 116,461 SH
19 IMMUNOVANT INC IMVT 45258J102 $10.7M 1.84% 276,527 SH
20 CELCUITY INC CELC 15102K100 $10.3M 1.77% 98,203 SH
21 RELMADA THERAPEUTICS INC RLMD 75955J402 $10.1M 1.74% 1,460,093 SH
22 CLIMB BIO INC CLYM 28658R106 $9.7M 1.67% 742,745 SH
23 SPYRE THERAPEUTICS INC SYRE 00773J202 $9.5M 1.64% 106,926 SH
24 ZURA BIO LTD ZURA G9TY5A101 $8.1M 1.39% 1,368,215 SH
25 INFLARX NV IFRX N44821101 $7.2M 1.25% 3,228,255 SH
26 SURROZEN INC SRZN 86889P208 $7.1M 1.22% 273,140 SH
27 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $6.9M 1.19% 384,304 SH
28 SURROZEN INC SRZN 86889P208 $6.7M 1.15% 329,658 SH
29 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $6.6M 1.14% 178,412 SH
30 OVID THERAPEUTICS INC OVID 690469101 $6.5M 1.12% 2,417,283 SH
31 EQUILLIUM INC EQ 29446K106 $6.5M 1.11% 2,016,607 SH
32 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $6.5M 1.11% 137,124 SH
33 CYTOKINETICS INC CYTK 23282W605 $6.4M 1.11% 75,603 SH
34 DAMORA THERAPEUTICS INC DMRA 36322Q206 $5.6M 0.97% 216,194 SH
35 INVENTIVA SA IVA 46124U107 $5.4M 0.93% 1,426,320 SH
36 CENTURY THERAPEUTICS INC IPSC 15673T100 $5.3M 0.91% 2,146,182 SH
37 AURA BIOSCIENCES INC AURA 05153U107 $5.1M 0.87% 714,280 SH
38 EYEPOINT INC EYPT 30233G209 $4.8M 0.83% 338,471 SH
39 ASSEMBLY BIOSCIENCES INC ASMB 045396207 $4.7M 0.81% 170,378 SH
40 WHITEHAWK THERAPEUTICS INC WHWK 00032Q104 $4.7M 0.81% 1,021,037 SH
41 XENON PHARMACEUTICALS INC XENE 98420N105 $4.6M 0.79% 76,075 SH
42 UNIQURE NV QURE N90064101 $4.1M 0.70% 88,115 SH
43 COMPASS PATHWAYS PLC CMPS 20451W101 $4.0M 0.69% 284,769 SH
44 AVALYN PHARMACEUTICALS INC AVLN 05348Y105 $3.9M 0.67% 118,000 SH
45 MAPLIGHT THERAPEUTICS INC MPLT 56565P103 $3.8M 0.66% 106,906 SH
46 ALUMIS INC ALMS 022307102 $3.8M 0.66% 135,736 SH
47 AXSOME THERAPEUTICS INC. AXSM 05464T104 $3.8M 0.65% 15,375 SH
48 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $3.7M 0.64% 153,544 SH
49 ACADIA PHARMACEUTICALS INC ACAD 004225108 $3.6M 0.62% 143,167 SH
50 SOLID BIOSCIENCES INC SLDB 83422E204 $3.6M 0.62% 358,780 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $580.5M 85 0001420506-26-001687
2026-03-31 2026-05-15 $514.6M 83 0001420506-26-001107
2026-03-31 2026-05-18 $522.3M 84 0001420506-26-001177
2025-12-31 2026-02-17 $583.2M 78 0001420506-26-000490
2025-09-30 2025-11-14 $499.1M 90 0001420506-25-003308
Filer Information
Address
520 MADISON AVENUE
19TH FLOOR
NEW YORK, NY 10022
Phone
(212) 540-4099
Filing Manager
STEMPOINT CAPITAL LP
NEW YORK, NY
Signatory
Sean Tan
President and Managing Partner